Moreover, in immune checkpoint therapy, the dense ECM acts as a physical obstacle that limits T-cell infiltration and reduces PD-1/PD-L1 interactions [80], thereby limiting the cytotoxicity of cancer cells. Here, CD274 is linked to cancer.